Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


15.04.2019

3 BMC Cancer
1 Br J Radiol
1 Cancer Lett
1 Cancer Res
1 Clin Cancer Res
7 Eur Urol
1 Int J Cancer
4 Int J Radiat Oncol Biol Phys
1 J Cell Physiol
1 J Clin Lab Anal
1 J Clin Oncol
1 J Nucl Med
5 J Urol
1 Lancet Oncol
1 Mod Pathol
2 Nat Rev Urol
4 PLoS One
4 Prostate
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. NEIL-SZTRAMKO SE, Medysky ME, Campbell KL, Bland KA, et al
    Attention to the principles of exercise training in exercise studies on prostate cancer survivors: a systematic review.
    BMC Cancer. 2019;19:321.
    PubMed     Text format     Abstract available

  2. TIWARI A, Mukherjee B, Hassan MK, Pattanaik N, et al
    Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.
    BMC Cancer. 2019;19:346.
    PubMed     Text format     Abstract available

  3. IGUCHI T, Tamada S, Kato M, Yasuda S, et al
    Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
    BMC Cancer. 2019;19:339.
    PubMed     Text format     Abstract available


    Br J Radiol

  4. GIACOMETTI V, King RB, Agnew CE, Irvine DM, et al
    An Evaluation of Techniques for Dose Calculation on Cone Beam Computed Tomography.
    Br J Radiol. 2018 Nov 15:20180383. doi: 10.1259/bjr.20180383.
    PubMed     Text format     Abstract available


    Cancer Lett

  5. KAPUR N, Mir H, Sonpavde G, Jain S, et al
    Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.
    Cancer Lett. 2019 Apr 8. pii: S0304-3835(19)30219.
    PubMed     Text format     Abstract available


    Cancer Res

  6. LI S, Fong KW, Gritsina G, Zhang A, et al
    Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer.
    Cancer Res. 2019 Apr 5. pii: 0008-5472.CAN-18-2812.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  7. LIU YN, Niu S, Chen WY, Zhang Q, et al
    Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46.
    Clin Cancer Res. 2019 Apr 8. pii: 1078-0432.CCR-18-3239.
    PubMed     Text format     Abstract available


    Eur Urol

  8. VAN DEN BROECK T, Mottet N, Lam T
    Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A System
    Eur Urol. 2019 Apr 6. pii: S0302-2838(19)30255.
    PubMed     Text format    

  9. SADUN TY, Reiter RE
    Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial.
    Eur Urol. 2019;75:591-592.
    PubMed     Text format    

  10. FRYDENBERG M
    Re: (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2019 Apr 4. pii: S0302-2838(19)30272.
    PubMed     Text format    

  11. MATEO J, Carreira S, de Bono JS
    PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.
    Eur Urol. 2019 Apr 3. pii: S0302-2838(19)30257.
    PubMed     Text format    

  12. STEINECK G, Akre O, Bill-Axelson A
    Solid Science for the Upside but Lack of Solid Science for the Downside-Towards Cutting-edge Prostate-cancer Screening.
    Eur Urol. 2019 Apr 8. pii: S0302-2838(19)30276.
    PubMed     Text format    

  13. CATHELINEAU X, Macek P, Sanchez-Salas R
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Apr 4. pii: S0302-2838(19)30262.
    PubMed     Text format    

  14. WERNTZ RP, Eggener SE
    Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015.
    Eur Urol. 2019 Apr 5. pii: S0302-2838(19)30274.
    PubMed     Text format    


    Int J Cancer

  15. GORODETSKA I, Lukiyanchuk V, Peitzsch C, Kozeretska I, et al
    BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32323.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  16. JACKSON WC, Silva J, Hartman HE, Dess RT, et al
    Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
    Int J Radiat Oncol Biol Phys. 2019 Apr 5. pii: S0360-3016(19)30612.
    PubMed     Text format     Abstract available

  17. HALLEMEIER CL, Zhang P, Pisansky TM, Hanks GE, et al
    Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials.
    Int J Radiat Oncol Biol Phys. 2019 Apr 5. pii: S0360-3016(19)30610.
    PubMed     Text format     Abstract available


  18. Erratum to: Wilkins AC, Gusterson B, Szijgyarto Z, et al. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2018;101:309-315
    Int J Radiat Oncol Biol Phys. 2019;104:226.
    PubMed     Text format    

  19. CHOUDHURY A, Chen RC, Henry A, Mistry H, et al
    STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2019;104:33-35.
    PubMed     Text format    


    J Cell Physiol

  20. AZIZI R, Salemi Z, Fallahian F, Aghaei M, et al
    Inhibition of didscoidin domain receptor 1 reduces epithelial-mesenchymal transition and induce cell-cycle arrest and apoptosis in prostate cancer cell lines.
    J Cell Physiol. 2019 Apr 8. doi: 10.1002/jcp.28552.
    PubMed     Text format     Abstract available


    J Clin Lab Anal

  21. DUAN X, Xu X, Yin B, Hong B, et al
    The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy.
    J Clin Lab Anal. 2019 Apr 8:e22871. doi: 10.1002/jcla.22871.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. GIRI VN, Hyatt C, Gomella LG
    Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management.
    J Clin Oncol. 2019 Apr 12:JCO1802181. doi: 10.1200/JCO.18.02181.
    PubMed     Text format    


    J Nucl Med

  23. ABIODUN-OJO OA, Akintayo AA, Akin-Akintayo OO, Tade FI, et al
    (18)F-Fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer.
    J Nucl Med. 2019 Apr 6. pii: jnumed.119.227033. doi: 10.2967/jnumed.119.227033.
    PubMed     Text format     Abstract available


    J Urol

  24. CEDARS BE, Washington SL 3rd, Cowan JE, Leapman M, et al
    STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER.
    J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271.
    PubMed     Text format     Abstract available

  25. TEWARI AK, Taouli B
    Radiomics features measured with multiparametric MRI predict prostate cancer aggressiveness.
    J Urol. 2019 Apr 8:101097JU0000000000000272. doi: 10.1097/JU.0000000000000272.
    PubMed     Text format     Abstract available

  26. TANEJA SS
    Re: Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
    J Urol. 2019 Apr 8:101097JU0000000000000276. doi: 10.1097/JU.0000000000000276.
    PubMed     Text format    

  27. TANEJA SS
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): a Randomised Controlled Phase 3 Trial.
    J Urol. 2019 Apr 8:10109701JU00005577560832916.
    PubMed     Text format    

  28. ADSHEAD J, Oldfield F, Hadaschik B, Wouter Everaerts JA, et al
    MP20-04 USABILITY AND TECHNICAL FEASIBILITY EVALUATION OF A TETHERED LAPAROSCOPIC GAMMA PROBE FOR RADIOGUIDED SURGERY IN PROSTATE CANCER: A PELVIC PHANTOM AND PORCINE MODEL STUDY.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


    Lancet Oncol

  29. GOURD E
    Addition of mitoxantrone and prednisone to ADT.
    Lancet Oncol. 2018;19:e336.
    PubMed     Text format    


    Mod Pathol

  30. KAMMERER-JACQUET SF, Ahmad A, Moller H, Sandu H, et al
    Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.
    Mod Pathol. 2019 Apr 11. pii: 10.1038/s41379-019-0268.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  31. KOO KM, Mainwaring PN, Tomlins SA, Trau M, et al
    Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management.
    Nat Rev Urol. 2019 Apr 8. pii: 10.1038/s41585-019-0178.
    PubMed     Text format     Abstract available

  32. GHAI S, Trachtenberg J
    Internet information on focal prostate cancer therapy: help or hindrance?
    Nat Rev Urol. 2019 Apr 5. pii: 10.1038/s41585-019-0180.
    PubMed     Text format    


    PLoS One

  33. SONG C, Byun SJ, Kim YS, Ahn H, et al
    Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis.
    PLoS One. 2019;14:e0215057.
    PubMed     Text format     Abstract available

  34. BRYZGUNOVA OE, Zaporozhchenko IA, Lekchnov EA, Amelina EV, et al
    Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer.
    PLoS One. 2019;14:e0215003.
    PubMed     Text format     Abstract available

  35. DERYCKE MS, Larson MC, Nair AA, McDonnell SK, et al
    An expanded variant list and assembly annotation identifies multiple novel coding and noncoding genes for prostate cancer risk using a normal prostate tissue eQTL data set.
    PLoS One. 2019;14:e0214588.
    PubMed     Text format     Abstract available

  36. MAUGHAM ML, Seim I, Thomas PB, Crisp GJ, et al
    No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction.
    PLoS One. 2018;13:e0198495.
    PubMed     Text format     Abstract available


    Prostate

  37. GHORBANMEHR N, Gharbi S, Korsching E, Tavallaei M, et al
    miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
    Prostate. 2018 Sep 7. doi: 10.1002/pros.23714.
    PubMed     Text format     Abstract available

  38. MCDONALD AC, Vira M, Walter V, Shen J, et al
    Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.
    Prostate. 2019 Apr 8. doi: 10.1002/pros.23803.
    PubMed     Text format     Abstract available

  39. KIM S, Zhang Y, Tang S, Qin C, et al
    Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice.
    Prostate. 2019 Apr 8. doi: 10.1002/pros.23802.
    PubMed     Text format     Abstract available

  40. GANG X, Xuan L, Zhao X, Lv Y, et al
    Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
    Prostate. 2019 Apr 7. doi: 10.1002/pros.23793.
    PubMed     Text format     Abstract available


    Urology

  41. SHELTON JB, Buffington P, Augspurger R, Gaylis F, et al
    Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United States.
    Urology. 2019 Apr 4. pii: S0090-4295(19)30326.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: